GlassScriptPhysician profile
Brandon K Bodlak
NPI 1144251810
$18,852.94
in general payments reported to CMS, 2019-2025
60 companies · $2,034 in 2025
The $2,034 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,633 · 2020: $2,205 · 2021: $3,064 · 2022: $3,024 · 2023: $3,165 · 2024: $2,729 · 2025: $2,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,916 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,916.28 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,518.29 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $2,204.92 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,869.23 | 2019-2025 | Jardiance, Synjardy |
| Abbvie INC. | $1,643.38 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $1,451.84 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,408.48 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $1,325.31 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $805.27 | 2019-2025 | Repatha, Otezla, Prolia |
| Janssen Pharmaceuticals, INC | $451.23 | 2019-2022 | |
| Abbott Laboratories | $391.04 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $366.62 | 2019-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $312.98 | 2019-2022 | |
| Amarin Pharma, INC. | $297.96 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $268.89 | 2023-2024 | Zeposia |
| Exact Sciences Corporation | $198.81 | 2023-2025 | Cologuard Collection Kit |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Bodlak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.